LIC MF Healthcare Fund Direct Growth

LIC MF Healthcare Fund Direct Growth

Equity

Direct

Sector - Healthcare

NAV as on 18-10-2024

₹ 32.48

Inception Returns

23.2%

/yr

About LIC MF Healthcare Fund Direct Growth

LIC MF Healthcare Fund Direct Growth is an equity fund. This fund was started on 28 February, 2019. The fund is managed by Karan Doshi. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. LIC MF Healthcare Fund Direct Growth has ₹75 Cr worth of assets under management (AUM) as on Sep 2024 and is less than category average.
  2. The fund has an expense ratio 1.2.

Returns

LIC MF Healthcare Fund Direct Growth has given a CAGR return of 23.24% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 59.31%, 16.22% and 26.37% respectively.

Holdings

LIC MF Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Piramal Pharma Ltd, Artemis Medicare Services Ltd Ordinary Shares, Torrent Pharmaceuticals Ltd, Glenmark Pharmaceuticals Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of LIC MF Healthcare Fund Direct Growth

The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. However there can be no assurance that the investment objective under the scheme will be realized.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 200.00. LIC MF Healthcare Fund Direct Growth has no lock in period.

Historical NAV & Returns

Annualised

zero opening, trading, fund transfer fee
30 people have invested ₹ 4.2L in LIC MF Healthcare Fund Direct Growth in the last three months

INDmoney Rank for LIC MF Healthcare Fund Direct Growth

Powered by IND quant engine
IND ranking is not available for this fund.
img
Beats FD returns for both 3Y & 5Y duration
img
5Y returns in the bottom 25% of the category
img
3Y returns in the bottom 25% of the category

LIC MF Healthcare Fund Direct Growth Overview

Expense ratio1.21%
Benchmark
S&P BSE Healthcare PR
AUM₹75 Cr
Inception Date28 February, 2019
Min Lumpsum/SIP₹5000/₹200
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
414.8%
STCGRedeeming before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

Trailing Returns

as on (18-Oct-24)

Period
LIC MF Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
2.6%
-3.1%
0.9%
3M
15.7%
2.6%
13.6%
6M
27.5%
15%
27.5%
1Y
59.3%
36.2%
55.3%
3Y
16.2%
14.6%
19%
5Y
26.4%
19.9%
29.3%

Fund Distribution

as on (30-Sep-24)

  • Equity 96.9%

  • Debt & Cash 3.1%

Large cap
40.7%

Small cap
31.4%

Mid cap
22.7%

Sector Allocation

Sep'24

Aug'24

Jul'24

Health
96.9%
Basic Materials
3.1%
All changes are between Jul'24 and Sep'24
Sep'24
Aug'24
Jul'24
Fund Returns
1.96%
6.10%
11.17%
Nifty 500
2.04%
0.97%
3.53%
  • This fund’s returns stands at 1.96% whereas the fund’s underlying benchmark Nifty 500 returns stands at 2.04% as on Sep'24
  • This fund underperformed Nifty 500 by 0.08% in Sep'24
Parameters
Sep'24
Aug'24
Jul'24
AUM
₹ 71.6 Cr
₹ 71.6 Cr
₹ 69.2 Cr
  • AUM of the fund stands at 71.6 Cr as of Sep'24
  • AUM has remained same between Sep'24 and Aug'24
Top Stocks bought last month
Neuland Laboratories Limited's allocation increased from 1% to 2.21%
Neuland Laboratories Limited's allocation increased from 1% to 2.21%
Piramal Pharma Ltd's allocation increased from 6.71% to 7.76%
Piramal Pharma Ltd's allocation increased from 6.71% to 7.76%
Navin Fluorine International Ltd's allocation increased from 2.41% to 2.91%
Navin Fluorine International Ltd's allocation increased from 2.41% to 2.91%
Top Stocks sold last month
Artemis Medicare Services Ltd Ordinary Shares's allocation decreased from 6.39 % to 6.06 %
Artemis Medicare Services Ltd Ordinary Shares's allocation decreased from 6.39 % to 6.06 %
Torrent Pharmaceuticals Ltd's allocation decreased from 6.03 % to 5.61 %
Torrent Pharmaceuticals Ltd's allocation decreased from 6.03 % to 5.61 %
Glenmark Pharmaceuticals Ltd's allocation decreased from 5.63 % to 5.19 %
Glenmark Pharmaceuticals Ltd's allocation decreased from 5.63 % to 5.19 %
Large Cap allocation has gone up from 37.9% to 40.7%
Large Cap allocation has gone up from 37.9% to 40.7%
Small Cap allocation has gone down from 34.4% to 31.4%
Small Cap allocation has gone down from 34.4% to 31.4%
Mid Cap allocation has gone down from 24.3% to 22.7%
Mid Cap allocation has gone down from 24.3% to 22.7%
Cash allocation has gone up from 2.5% to 3.1%
Cash allocation has gone up from 2.5% to 3.1%

Top 2 Sectors in September were Health, Basic Materials

Sep'24
Health
97%
Basic Materials
3%
Aug'24
Health
96%
Basic Materials
4%
Fund
Sep'24
Aug'24
Jul'24
No of Holdings
25
26
23
Top 5 Company Concentration
36%
36%
37.2%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (11.4%)
Sun Pharmaceuticals Industries Ltd (11.3%)
Sun Pharmaceuticals Industries Ltd (11.5%)
No of Sectors
2
2
2
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (96.9%)
Health (96.5%)
Health (97.7%)
Loading...
We are taking more time than usual
Karan Doshi
Karan Doshi
Fund Manager of LIC MF Healthcare Fund Direct Growth, since 31 July 2023
Fund House
LIC Mutual Fund Asset Management Limited
Total Schemes
Total AUM
₹28.62K Cr
as on 30-Sep-2024
Address
LIC Mutual Fund Asset Management Limited,4th Floor, Industrial Assurance Building,,Opp. Churchgate Station,
Phone
+91022-66016000
Website
licmfamc@licmutual.com

Mutual Fund Insights

Insights icon
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 63.82% return, outperforming this fund by 4.51%.
Insights icon
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 23.52% return, outperforming this fund by 7.3% per annum.
Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.21% which is lower than the category average expense ratio of 1.39%.
Insights icon
Over the last 3 months, this fund has experienced a 21.0% growth in AUM moving from 62.03 Cr to 75.05 Cr.
Insights icon
In the last 5 years, DSP Healthcare Fund Direct Growth has given 34.35% return, outperforming this fund by 7.99% per annum.

LIC MF Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 23.24% since inception which is less than its category average return of 27.8%
Fund Allocations

Fund Allocations

This fund has an allocation of 96.92% in Equity, 0% in Debt and 3.08% in Cash related instruments
AUM size ₹0 Cr

AUM size ₹0 Cr

This fund has AUM of ₹0 Cr which is less than its category average of ₹ 2128 Cr
Expense Ratio 1.21%

Expense Ratio 1.21%

This fund has an expense ratio of 1.21% which is less than its category average expense ratio of 1.41%

Frequently Asked Questions for LIC MF Healthcare Fund Direct Growth

The current NAV of LIC MF Healthcare Fund Direct Growth is ₹32.48 as on 18-Oct-2024.
Existing (Absolute + CAGR) as on 18-Oct-2024.
LIC MF Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
2.65%
2.65%
6 Month Returns
27.55%
27.55%
1 Year Returns
59.31%
59.31%
3 Years Returns
56.98%
16.22%
5 Years Returns
222.22%
26.37%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.21% as on September 2024
₹75 Cr as on September 2024
Sun Pharmaceuticals Industries Ltd(11.4%), Piramal Pharma Ltd(7.76%), Artemis Medicare Services Ltd Ordinary Shares(6.06%), Torrent Pharmaceuticals Ltd(5.61%), Glenmark Pharmaceuticals Ltd(5.19%) as on September 2024
The alpha ratio for the LIC MF Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
LIC MF Healthcare Fund Direct Growth
1.96
-2.11
-0.48
As on September 2024
The alpha for LIC MF Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the LIC MF Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
LIC MF Healthcare Fund Direct Growth
0.95
0.94
0.92
As on September 2024
The Beta for LIC MF Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the LIC MF Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
LIC MF Healthcare Fund Direct Growth
2.52
0.66
1.09
As on September 2024
The sharpe ratio for LIC MF Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the LIC MF Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
LIC MF Healthcare Fund Direct Growth
15.5
15.63
18.42
As on September 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.16 as on September 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Karan Doshi is the fund manager of LIC MF Healthcare Fund Direct Growth
The Exit load of LIC MF Healthcare Fund Direct Growth is 1%